Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Point-Of-Care Test to Transform Early-Stage Cervical Cancer Diagnosis

By LabMedica International staff writers
Posted on 27 Jun 2025

Cervical cancer is the world’s fourth most common cancer in women. More...

When it’s found early, it’s one of the most preventable and treatable cancers. The main screening method is an in-person Pap smear. The FDA recently approved the first at-home self-collection device, which screens for HPV, the virus that causes nearly all cervical cancers. Still, these methods can be expensive, time-consuming, and not always available. Now, a new method based on measuring cellular proteins could reduce the need for expensive laboratory equipment and training.

Researchers are now one step closer to developing a simple, at-home test to prevent cervical cancer or treat it early, according to a new study by researchers from the University of Florida Health Cancer Center (Gainesville, FL, USA) and Purdue University (West Lafayette, IN, USA). In the new study, researchers validated four proteins that were more abundant in swabs from women with high-grade precancerous lesions and tissue samples from patients. The results, published in the journal Cancers, show that the researchers found the proteins could be used as sensitive and specific biomarkers to indicate precancerous lesions and to distinguish subtypes of cervical cancer.

Precancerous lesions can usually be successfully treated, preventing cancer from developing. Knowing the subtype tells health care providers how aggressive or fast-moving the cancer is, helping them develop a treatment plan. Next, the researchers plan to develop a standardized way to collect and process cervical cancer samples, paving the way for a point-of-care test. Point-of-care tests are portable tests that can be done in more convenient settings than a traditional medical laboratory, and they’re usually faster.

“Our results pave the way for us to develop inexpensive, fast and accurate preliminary screening tests for cervical cancer,” said Sulma Mohammed, D.V.M., Ph.D., the study’s senior author. “This test has the potential to transform early-stage cervical cancer diagnosis and treatment, particularly in areas with limited access to health care.”

Related Links:
UF Health Cancer Center 


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.